SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

vormatrigine

PRAX·Praxis Precision Medicines, Inc.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 3
Time to market
If the Phase 3 trial reads out positive in early 2027, an NDA filing could follow later in 2027 or 2028, putting potential approval at least 2-3 years away. The drug is not yet filed with the FDA.
Why 5/10
The next hard catalyst is the estimated primary completion of the Phase 3 focal seizure trial in January 2027 (about 2 months away), which could trigger a topline data readout. However, vormatrigine is a secondary pipeline asset behind relutrigine and ulixacaltamide (both with imminent PDUFA dates), so it is not the company's primary value driver.
Actionable Insight NEUTRAL

Watch for the Phase 3 topline data readout for vormatrigine, expected around the estimated primary completion date of January 2027. A positive readout would add a third late-stage pipeline asset to Praxis, while a negative result would be a setback but likely not catastrophic given the company's two lead PDUFA catalysts (relutrigine Dec 27, 2026 and ulixacaltamide Jan 29, 2027). The company's Investor Day on November 12, 2026 may provide additional pipeline updates.

Price Chart

Loading chart...

Executive Summary

Vormatrigine is Praxis Precision Medicines' Phase 3 oral anti-seizure drug candidate for focal epilepsy. A 300-patient randomized trial (NCT07505004) completed enrollment and is active but not recruiting, with estimated primary completion in January 2027. The drug is a secondary pipeline asset behind the company's two lead programs (relutrigine with a December 27, 2026 PDUFA and ulixacaltamide with a January 29, 2027 PDUFA), which together drive most of the company's valuation. Praxis has $1.3 billion in cash, strong analyst support (mean price target $650 vs ~$333 current), and a cash runway into 2028. The focal epilepsy market is large, but the Phase 3 readout carries binary risk and the program is less advanced than the company's two lead NDA-stage assets.

How It Works

Vormatrigine is an oral anti-seizure medication being developed for focal epilepsy (seizures that start in one area of the brain). While its exact mechanism is not publicly detailed, it belongs to Praxis's precision neuroscience platform targeting ion channel and neuronal excitability disorders.

Trial Status

Vormatrigine is in a Phase 3 randomized clinical trial (NCT07505004) evaluating its efficacy and safety in adults with focal seizures. The trial enrolled approximately 300 patients across three dose arms (20, 30, and 40 mg/day for 12 weeks). Enrollment is complete and the trial is active but not recruiting. It started in January 2026, with estimated primary completion in January 2027 and final completion in May 2027. A separate Phase 3 trial for PRAX-628 (POWER1 study) in focal seizures completed in May 2026, which may be the same molecule under an earlier development code.

The Two-Sided Case

▲ Bull Case4
Focal epilepsy is a large market with significant unmet need; a new oral anti-seizure drug with a favorable profile could capture meaningful share.
Praxis has deep expertise in CNS precision neuroscience and a track record of advancing drugs to Phase 3 and NDA filing (relutrigine, ulixacaltamide).
The company has $1.3 billion in cash and runway into 2028, providing ample resources to complete the vormatrigine program without financing risk.
Analyst consensus is strongly bullish on PRAX (15 Buy, 9 Strong Buy, 2 Hold, 0 Sell) with a mean price target of $650, implying ~95% upside from the $333 close on Nov 9, 2026.
▼ Bear Case4
Vormatrigine is a secondary pipeline asset behind relutrigine (PDUFA Dec 27, 2026) and ulixacaltamide (PDUFA Jan 29, 2027), which together drive most of the company's valuation.
The Phase 3 trial is still ongoing with estimated primary completion in January 2027; there is no guarantee of positive topline results, and focal seizure trials have a history of mixed outcomes.
PRAX-628, a separate Phase 3 focal seizure program (POWER1), completed in May 2026 with no publicly reported results, which could signal challenges in this indication.
The company has no approved products and no revenue; any pipeline setback could significantly impact the stock.

Upcoming Catalysts

  • Estimated primary completion of Phase 3 focal seizure trial (January 2027) - topline data readout likely thereafter
  • Praxis Precision Medicines Investor Day on November 12, 2026 - may provide pipeline updates including vormatrigine

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Praxis Precision Medicines, Inc. PRESS-RELEASE PRAX ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 quiverquant.com3 finviz.com4 seekingalpha.com